SCHEMBL6207475

SCHEMBL6207475

CN(C)CCCNc1nnc(-c2ccc(F)c(F)c2Nc2ccc(I)cc2F)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 15/20 0.41
MAP2K2 P36507 12/20 0.41
CHRNA7 P36544 1/20 0.41
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
KDR P35968 1/20 0.39
PIM1 P11309 1/20 0.38
CAMK2B Q13554 1/20 0.38
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6188396 0.94 MAP2K1 (0.43) MAP2K1MAP2K2CHRNA7PIM1CAMK2B
SCHEMBL6207534 0.91 CHRNA7 (0.43) MAP2K1MAP2K2CHRNA7CYP3A4CYP2C9
SCHEMBL6399813 0.90 MAP2K1 (0.43) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6187354 0.90 MAP2K1 (0.48) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6186483 0.89 MAP2K1 (0.47) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6190178 0.88 MAP2K1 (0.46) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6208327 0.88 MAP2K1 (0.52) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6187892 0.88 MAP2K1 (0.45) MAP2K1MAP2K2CYP3A4KDRPIM1
SCHEMBL21067809 0.87 MAP2K1 (0.46) MAP2K1MAP2K2PIM1CAMK2BHDAC3
SCHEMBL6406299 0.87 PIM1 (0.44) MAP2K1MAP2K2CHRNA7CYP3A4PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 MAP2K1 46/4885MAP2K2 40/4885CHRNA7 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.